{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:57:06Z","timestamp":1781650626460,"version":"3.54.5"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81873444"],"award-info":[{"award-number":["No.81873444"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a well-established treatment for a range of medical conditions. However, the procedure carries with it a significant risk of chronic graft-versus-host disease (cGVHD), which can have a considerable impact on patients\u2019 quality of life and clinical outcomes. In recent years, there has been a marked shift in treatment strategies for this condition, with greater emphasis being placed on novel targeted therapies and cell therapies that target specific pathways. This shift in approach signifies a more profound comprehension of the pathogenesis of the condition, particularly with respect to abnormal T\/B cell activation, tissue fibrosis progression, and immune tolerance imbalance. This article systematically reviews the current treatment framework and latest advances in cGVHD, covering the evolution from first-line immunosuppression to diverse precision targeted drugs and cellular therapy strategies. The study methodically analyses their positioning in clinical practice and the challenges encountered, with the objective of providing theoretical support and practical guidance for refined, individualised clinical management of cGVHD.<\/jats:p>","DOI":"10.1007\/s12015-026-11131-7","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T09:43:45Z","timestamp":1776678225000},"page":"2159-2186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving Paradigms in Chronic Graft-Versus-Host Disease: From Global Immunosuppression to Precision Targeted and Cell-Based Therapies"],"prefix":"10.1007","volume":"22","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"1","key":"11131_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","volume":"129","author":"SJ Lee","year":"2017","unstructured":"Lee, S. J. (2017). Classification systems for chronic graft-versus-host disease. Blood, 129(1), 30\u201337. https:\/\/doi.org\/10.1182\/blood-2016-07-686642","journal-title":"Blood"},{"issue":"12","key":"11131_CR2","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.bbmt.2019.07.040","volume":"25","author":"JA Pidala","year":"2019","unstructured":"Pidala, J. A., Hamilton, B. K., Martin, P. J., et al. (2019). The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) index. Biology of Blood and Marrow Transplantation, 25(12), 2468\u20132473. https:\/\/doi.org\/10.1016\/j.bbmt.2019.07.040","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"12","key":"11131_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061476","volume":"12","author":"S Kulkarni","year":"2022","unstructured":"Kulkarni, S., Durham, H., Glover, L., et al. (2022). Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis. BMJ Open, 12(12), Article e61476. https:\/\/doi.org\/10.1136\/bmjopen-2022-061476","journal-title":"BMJ Open"},{"issue":"8","key":"11131_CR4","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41409-024-02289-0","volume":"59","author":"F Ayuk","year":"2024","unstructured":"Ayuk, F., Wagner-Drouet, E. M., Wolff, D., et al. (2024). Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): A prospective multicenter phase IIA study. Bone Marrow Transplantation, 59(8), 1092\u20131096. https:\/\/doi.org\/10.1038\/s41409-024-02289-0","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"11131_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2022.12.024","volume":"90","author":"E Baumrin","year":"2024","unstructured":"Baumrin, E., Loren, A. W., Falk, S. J., et al. (2024). Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations. Journal of the American Academy of Dermatology, 90(1), 1\u201316. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.024","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"11131_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaad.2022.12.023","volume":"90","author":"E Baumrin","year":"2024","unstructured":"Baumrin, E., Loren, A. W., Falk, S. J., et al. (2024). Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management. Journal of the American Academy of Dermatology, 90(1), 19\u201336. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.023","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"11","key":"11131_CR7","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1007\/s00520-021-06197-7","volume":"29","author":"J Stolze","year":"2021","unstructured":"Stolze, J., Boor, M., Hazenberg, M. D., et al. (2021). Oral health-related quality of life of patients with oral chronic graft-versus-host disease. Supportive Care in Cancer, 29(11), 6353\u20136360. https:\/\/doi.org\/10.1007\/s00520-021-06197-7","journal-title":"Supportive Care in Cancer"},{"key":"11131_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.09.030","author":"V Ardila","year":"2025","unstructured":"Ardila, V., Onstad, L., Carpenter, P., et al. (2025). Obesity Associations with Chronic Graft-Versus-Host Disease[J]. Transplant Cell Ther. https:\/\/doi.org\/10.1016\/j.jtct.2025.09.030","journal-title":"Transplant Cell Ther"},{"key":"11131_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70074","author":"XC Tsai","year":"2025","unstructured":"Tsai, X. C., Yao, Z. H., Chou, S. W., et al. (2025). Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM). British Journal of Haematology. https:\/\/doi.org\/10.1111\/bjh.70074","journal-title":"British Journal of Haematology"},{"key":"11131_CR10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01727-2023","author":"S Bos","year":"2024","unstructured":"Bos, S., Murray, J., Marchetti, M., et al. (2024). ERS\/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults. European Respiratory Journal. https:\/\/doi.org\/10.1183\/13993003.01727-2023","journal-title":"European Respiratory Journal"},{"issue":"2","key":"11131_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/ejh.12149","volume":"91","author":"P Fraile","year":"2013","unstructured":"Fraile, P., Vazquez, L., Caballero, D., et al. (2013). Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant. European Journal of Haematology, 91(2), 129\u2013134. https:\/\/doi.org\/10.1111\/ejh.12149","journal-title":"European Journal of Haematology"},{"issue":"3","key":"11131_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia, M. H., Greinix, H. T., Arora, M., et al. (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report[J]. Biology of blood and marrow transplantation: Journal of the American Society for Blood and Marrow Transplantation, 21(3), 389\u2013401. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biology of blood and marrow transplantation: Journal of the American Society for Blood and Marrow Transplantation"},{"issue":"11","key":"11131_CR13","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/s41409-025-02697-w","volume":"60","author":"D Pulanic","year":"2025","unstructured":"Pulanic, D., Peczynski, C., Boreland, W., et al. (2025). Chronic Graft-versus-Host disease trends over 30 years - A study by the EBMT transplant complications working party. Bone Marrow Transplantation, 60(11), 1436\u20131444. https:\/\/doi.org\/10.1038\/s41409-025-02697-w","journal-title":"Bone Marrow Transplantation"},{"issue":"11","key":"11131_CR14","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","volume":"117","author":"MED Flowers","year":"2011","unstructured":"Flowers, M. E. D., Inamoto, Y., Carpenter, P. A., et al. (2011). Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood, 117(11), 3214\u20133219. https:\/\/doi.org\/10.1182\/blood-2010-08-302109","journal-title":"Blood"},{"issue":"3","key":"11131_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.bbmt.2017.11.004","volume":"24","author":"M Qayed","year":"2018","unstructured":"Qayed, M., Wang, T., Hemmer, M. T., et al. (2018). Influence of age on acute and chronic GVHD in children undergoing HLA-identical sibling bone marrow transplantation for acute leukemia: Implications for prophylaxis. Biology of Blood and Marrow Transplantation, 24(3), 521\u2013528. https:\/\/doi.org\/10.1016\/j.bbmt.2017.11.004","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"6","key":"11131_CR16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/s41375-025-02619-1","volume":"39","author":"O Penack","year":"2025","unstructured":"Penack, O., Abouqateb, M., Peczynski, C., et al. (2025). GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party. Leukemia, 39(6), 1503\u20131511. https:\/\/doi.org\/10.1038\/s41375-025-02619-1","journal-title":"Leukemia"},{"key":"11131_CR17","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.937356","volume":"27","author":"S Fang","year":"2022","unstructured":"Fang, S., Wang, N., Wang, L., et al. (2022). Reduced risk of chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in patients undergoing matched sibling donor transplantation in hematological malignancies. Annals of Transplantation, 27, Article e937356. https:\/\/doi.org\/10.12659\/AOT.937356","journal-title":"Annals of Transplantation"},{"issue":"5","key":"11131_CR18","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3109\/10428194.2011.634039","volume":"53","author":"Q Bashir","year":"2012","unstructured":"Bashir, Q., Munsell, M. F., Giralt, S., et al. (2012). Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leukemia & Lymphoma, 53(5), 915\u2013919. https:\/\/doi.org\/10.3109\/10428194.2011.634039","journal-title":"Leukemia & Lymphoma"},{"issue":"15","key":"11131_CR19","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1182\/bloodadvances.2023009791","volume":"7","author":"K Maurer","year":"2023","unstructured":"Maurer, K., Ho, V. T., Inyang, E., et al. (2023). Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: Lower incidence of relapse and chronic GVHD. Blood Advances, 7(15), 3903\u20133915. https:\/\/doi.org\/10.1182\/bloodadvances.2023009791","journal-title":"Blood Advances"},{"issue":"16","key":"11131_CR20","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti, C., Logan, B. R., Lee, S. J., et al. (2012). Peripheral-blood stem cells versus bone marrow from unrelated donors. The New England Journal of Medicine, 367(16), 1487\u20131496. https:\/\/doi.org\/10.1056\/NEJMoa1203517","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"11131_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2346401","volume":"29","author":"MG Meade","year":"2024","unstructured":"Meade, M. G., & Bolanos-Meade, J. (2024). The history of haploidentical stem cell transplantation: A trip from the bench to the bedside. Hematology, 29(1), Article 2346401. https:\/\/doi.org\/10.1080\/16078454.2024.2346401","journal-title":"Hematology"},{"issue":"1","key":"11131_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s12185-024-03871-4","volume":"121","author":"K Miyao","year":"2025","unstructured":"Miyao, K., Murata, M., Nishida, T., et al. (2025). Association between early anti-cytomegalovirus therapy and the incidence of chronic graft-versus-host disease. International Journal of Hematology, 121(1), 110\u2013125. https:\/\/doi.org\/10.1007\/s12185-024-03871-4","journal-title":"International Journal of Hematology"},{"issue":"1","key":"11131_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bjd.12828","volume":"171","author":"M Jachiet","year":"2014","unstructured":"Jachiet, M., de Masson, A., Peffault, D. L. R., et al. (2014). Skin ulcers related to chronic graft-versus-host disease: Clinical findings and associated morbidity[J]. British Journal Of Dermatology, 171(1), 63\u201368. https:\/\/doi.org\/10.1111\/bjd.12828","journal-title":"British Journal Of Dermatology"},{"issue":"4","key":"11131_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamadermatol.2023.6277","volume":"160","author":"E Baumrin","year":"2024","unstructured":"Baumrin, E., Shin, D. B., Mitra, N., et al. (2024). Patient-reported outcomes and mortality in cutaneous chronic Graft-vs-Host disease. JAMA Dermatology, 160(4), 393\u2013401. https:\/\/doi.org\/10.1001\/jamadermatol.2023.6277","journal-title":"JAMA Dermatology"},{"issue":"8","key":"11131_CR25","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3760\/cma.j.cn121090-20240611-00217","volume":"45","author":"[Chinese expert consensus on the diagnosis","year":"2024","unstructured":"[Chinese expert consensus on the diagnosis. (2024). and treatment of chronic graft-versus-host disease (2024)][J]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 45(8), 713\u2013726. https:\/\/doi.org\/10.3760\/cma.j.cn121090-20240611-00217","journal-title":"Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi"},{"issue":"15","key":"11131_CR26","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1182\/blood-2011-03-344390","volume":"118","author":"S Arai","year":"2011","unstructured":"Arai, S., Jagasia, M., Storer, B., et al. (2011). Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood, 118(15), 4242\u20134249. https:\/\/doi.org\/10.1182\/blood-2011-03-344390","journal-title":"Blood"},{"issue":"2","key":"11131_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","volume":"23","author":"KR Cooke","year":"2017","unstructured":"Cooke, K. R., Luznik, L., Sarantopoulos, S., et al. (2017). The biology of chronic graft-versus-host disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation\u202f: Journal of the American Society for Blood and Marrow Transplantation, 23(2), 211\u2013234. https:\/\/doi.org\/10.1016\/j.bbmt.2016.09.023","journal-title":"Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation"},{"issue":"2","key":"11131_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","volume":"23","author":"KR Cooke","year":"2017","unstructured":"Cooke, K. R., Luznik, L., Sarantopoulos, S., et al. (2017). The biology of chronic graft-versus-host disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 23(2), 211\u2013234. https:\/\/doi.org\/10.1016\/j.bbmt.2016.09.023","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"12","key":"11131_CR29","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1182\/blood-2004-12-4980","volume":"105","author":"E Tivol","year":"2005","unstructured":"Tivol, E., Komorowski, R., & Drobyski, W. R. (2005). Emergent autoimmunity in graft-versus-host disease. Blood, 105(12), 4885\u20134891. https:\/\/doi.org\/10.1182\/blood-2004-12-4980","journal-title":"Blood"},{"issue":"10","key":"11131_CR30","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41409-024-02370-8","volume":"59","author":"G Vadakkel","year":"2024","unstructured":"Vadakkel, G., Eng, S., Proli, A., et al. (2024). Updates in chronic graft-versus-host disease: Novel treatments and best practices in the current era. Bone Marrow Transplantation, 59(10), 1360\u20131368. https:\/\/doi.org\/10.1038\/s41409-024-02370-8","journal-title":"Bone Marrow Transplantation"},{"issue":"24","key":"11131_CR31","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1182\/blood-2016-02-697250","volume":"127","author":"M Koyama","year":"2016","unstructured":"Koyama, M., & Hill, G. R. (2016). Alloantigen presentation and graft-versus-host disease: Fuel for the fire. Blood, 127(24), 2963\u20132970. https:\/\/doi.org\/10.1182\/blood-2016-02-697250","journal-title":"Blood"},{"issue":"6","key":"11131_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000581","volume":"5","author":"LM Braun","year":"2021","unstructured":"Braun, L. M., & Zeiser, R. (2021). Immunomodulatory therapies for the treatment of graft-versus-host disease. Hemasphere, 5(6), Article e581. https:\/\/doi.org\/10.1097\/HS9.0000000000000581","journal-title":"Hemasphere"},{"issue":"7","key":"11131_CR33","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1182\/blood-2010-10-307819","volume":"117","author":"S Sarantopoulos","year":"2011","unstructured":"Sarantopoulos, S., Stevenson, K. E., Kim, H. T., et al. (2011). Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood, 117(7), 2275\u20132283. https:\/\/doi.org\/10.1182\/blood-2010-10-307819","journal-title":"Blood"},{"issue":"12","key":"11131_CR34","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1182\/blood-2012-06-438911","volume":"120","author":"JL Allen","year":"2012","unstructured":"Allen, J. L., Fore, M. S., Wooten, J., et al. (2012). B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood, 120(12), 2529\u20132536. https:\/\/doi.org\/10.1182\/blood-2012-06-438911","journal-title":"Blood"},{"issue":"20","key":"11131_CR35","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2015-12-688895","volume":"127","author":"E Forcade","year":"2016","unstructured":"Forcade, E., Kim, H. T., Cutler, C., et al. (2016). Circulating t follicular helper cells with increased function during chronic graft-versus-host disease. Blood, 127(20), 2489\u20132497. https:\/\/doi.org\/10.1182\/blood-2015-12-688895","journal-title":"Blood"},{"issue":"1","key":"11131_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-07918-2","volume":"15","author":"LJ Randall","year":"2025","unstructured":"Randall, L. J., Bajan, S., Tran, T. D., et al. (2025). <article-title update=\"added\">Propolis compound inhibits profibrotic TGF-\u03b21\/SMAD signalling in human fibroblasts. Scientific Reports, 15(1), Article 27260. https:\/\/doi.org\/10.1038\/s41598-025-07918-2","journal-title":"Scientific Reports"},{"issue":"1","key":"11131_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-07918-2","volume":"15","author":"LJ Randall","year":"2025","unstructured":"Randall, L. J., Bajan, S., Tran, T. D., et al. (2025). Propolis compound inhibits profibrotic TGF-\u03b21\/SMAD signalling in human fibroblasts. Scientific Reports, 15(1), Article 27260. https:\/\/doi.org\/10.1038\/s41598-025-07918-2","journal-title":"Scientific Reports"},{"key":"11131_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108823","volume":"230","author":"A Zanin-Zhorov","year":"2021","unstructured":"Zanin-Zhorov, A., & Blazar, B. R. (2021). ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease. Clinical Immunology, 230, Article 108823. https:\/\/doi.org\/10.1016\/j.clim.2021.108823","journal-title":"Clinical Immunology"},{"issue":"1","key":"11131_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-023-05552-0","volume":"6","author":"A Zanin-Zhorov","year":"2023","unstructured":"Zanin-Zhorov, A., Chen, W., Moretti, J., et al. (2023). Selectivity matters: Selective ROCK2 inhibitor ameliorates established liver fibrosis via targeting inflammation, fibrosis, and metabolism. Communications Biology, 6(1), Article 1176. https:\/\/doi.org\/10.1038\/s42003-023-05552-0","journal-title":"Communications Biology"},{"issue":"26","key":"11131_CR40","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser, R., & Blazar, B. R. (2017). Pathophysiology of chronic graft-versus-host disease and therapeutic targets. The New England Journal of Medicine, 377(26), 2565\u20132579. https:\/\/doi.org\/10.1056\/NEJMra1703472","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"11131_CR41","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jtct.2022.06.014","volume":"28","author":"K Yoshimura","year":"2022","unstructured":"Yoshimura, K., Kimura, S. I., Nakasone, H., et al. (2022). Low-Intensity Immunosuppressive Therapy for Chronic Graft-versus-Host Disease[J]. Transplant Cell Ther, 28(9), 591\u2013597. https:\/\/doi.org\/10.1016\/j.jtct.2022.06.014","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"11131_CR42","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jtct.2025.04.017","volume":"31","author":"A Denk","year":"2025","unstructured":"Denk, A., Fante, M. A., Heidenreich, S., et al. (2025). Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland[J]. Transplant Cell Ther, 31(7), 450\u2013451. https:\/\/doi.org\/10.1016\/j.jtct.2025.04.017","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"11131_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1182\/bloodadvances.2021005552","volume":"6","author":"A Lazaryan","year":"2022","unstructured":"Lazaryan, A., Lee, S., Arora, M., et al. (2022). A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Advances, 6(1), 259\u2013269. https:\/\/doi.org\/10.1182\/bloodadvances.2021005552","journal-title":"Blood Advances"},{"issue":"21","key":"11131_CR44","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","volume":"113","author":"PJ Martin","year":"2009","unstructured":"Martin, P. J., Storer, B. E., Rowley, S. D., et al. (2009). Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood, 113(21), 5074\u20135082. https:\/\/doi.org\/10.1182\/blood-2009-02-202937","journal-title":"Blood"},{"issue":"11","key":"11131_CR45","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.3324\/haematol.2018.195123","volume":"103","author":"PA Carpenter","year":"2018","unstructured":"Carpenter, P. A., Logan, B. R., Lee, S. J., et al. (2018). A phase II\/III randomized, multicenter trial of prednisone\/sirolimus versus prednisone\/ sirolimus\/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. Haematologica, 103(11), 1915\u20131924. https:\/\/doi.org\/10.3324\/haematol.2018.195123","journal-title":"Haematologica"},{"issue":"5","key":"11131_CR46","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/bbmt.2001.v7.pm11400948","volume":"7","author":"M Arora","year":"2001","unstructured":"Arora, M., Wagner, J. E., Davies, S. M., et al. (2001). Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation\u202f: Journal of the American Society for Blood and Marrow Transplantation, 7(5), 265\u2013273. https:\/\/doi.org\/10.1053\/bbmt.2001.v7.pm11400948","journal-title":"Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation"},{"issue":"4","key":"11131_CR47","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","volume":"125","author":"ME Flowers","year":"2015","unstructured":"Flowers, M. E., & Martin, P. J. (2015). How we treat chronic graft-versus-host disease. Blood, 125(4), 606\u2013615. https:\/\/doi.org\/10.1182\/blood-2014-08-551994","journal-title":"Blood"},{"issue":"5","key":"11131_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002024","volume":"13","author":"L Fardet","year":"2016","unstructured":"Fardet, L., Petersen, I., & Nazareth, I. (2016). Common infections in patients prescribed systemic glucocorticoids in primary care: A population-based cohort study. PLoS Medicine, 13(5), Article e1002024. https:\/\/doi.org\/10.1371\/journal.pmed.1002024","journal-title":"PLoS Medicine"},{"issue":"11","key":"11131_CR49","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S1470-2045(10)70114-5","volume":"11","author":"H Inaba","year":"2010","unstructured":"Inaba, H., & Pui, C. H. (2010). Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncology, 11(11), 1096\u20131106. https:\/\/doi.org\/10.1016\/S1470-2045(10)70114-5","journal-title":"Lancet Oncology"},{"issue":"4","key":"11131_CR50","doi-asserted-by":"publisher","first-page":"74","DOI":"10.46989\/001c.124926","volume":"6","author":"R Shah","year":"2024","unstructured":"Shah, R., Murphy, D., Logue, M., et al. (2024). Multidisciplinary management of morbidities associated with chronic graft-versus-host disease. Clinical Hematology International, 6(4), 74\u201388. https:\/\/doi.org\/10.46989\/001c.124926","journal-title":"Clinical Hematology International"},{"issue":"15","key":"11131_CR51","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","volume":"2","author":"SM Jaglowski","year":"2018","unstructured":"Jaglowski, S. M., & Blazar, B. R. (2018). How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Advances, 2(15), 2012\u20132019. https:\/\/doi.org\/10.1182\/bloodadvances.2018013060","journal-title":"Blood Advances"},{"key":"11131_CR52","doi-asserted-by":"crossref","unstructured":"Khangura, S. D., & Grobelna, A. (2022). Ibrutinib for Chronic Graft-Versus-Host Disease: Rapid Review[M]. Canadian Agency for Drugs and Technologies in Health.","DOI":"10.51731\/cjht.2022.368"},{"issue":"3","key":"11131_CR53","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser, R., Polverelli, N., Ram, R., et al. (2021). Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. The New England Journal of Medicine, 385(3), 228\u2013238. https:\/\/doi.org\/10.1056\/NEJMoa2033122","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"11131_CR54","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1111\/imj.16255","volume":"53","author":"N Hamad","year":"2023","unstructured":"Hamad, N., Bilmon, I., Chee, L., et al. (2023). ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease. Internal Medicine Journal, 53(12), 2319\u20132329. https:\/\/doi.org\/10.1111\/imj.16255","journal-title":"Internal Medicine Journal"},{"issue":"12","key":"11131_CR55","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-21-4176","volume":"28","author":"D Przepiorka","year":"2022","unstructured":"Przepiorka, D., Le, R. Q., Ionan, A., et al. (2022). FDA approval summary: Belumosudil for adult and pediatric patients 12 years and older with chronic GvHD after two or more prior lines of systemic therapy. Clinical Cancer Research, 28(12), 2488\u20132492. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4176","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"11131_CR56","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/ddg.14206","volume":"19","author":"B Walz","year":"2021","unstructured":"Walz, B., Maier, C. P., Beck, V., et al. (2021). Treatment of graft versus host disease with methotrexate after allogeneic hematopoietic stem cell transplantation. Journal der Deutschen Dermatologischen Gesellschaft, 19(1), 109\u2013111. https:\/\/doi.org\/10.1111\/ddg.14206","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"18","key":"11131_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cells13181524","volume":"13","author":"A Olivieri","year":"2024","unstructured":"Olivieri, A., & Mancini, G. (2024). Current approaches for the prevention and treatment of acute and chronic GVHD. Cells, 13(18), Article 1524. https:\/\/doi.org\/10.3390\/cells13181524","journal-title":"Cells"},{"issue":"3","key":"11131_CR58","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/rheumatology\/kem279","volume":"47","author":"JAM Wessels","year":"2008","unstructured":"Wessels, J. A. M., Huizinga, T. W. J., & Guchelaar, H. (2008). Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford, England), 47(3), 249\u2013255. https:\/\/doi.org\/10.1093\/rheumatology\/kem279","journal-title":"Rheumatology (Oxford, England)"},{"issue":"2","key":"11131_CR59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1124\/pr.57.2.3","volume":"57","author":"BN Cronstein","year":"2005","unstructured":"Cronstein, B. N. (2005). Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis. Pharmacological Reviews, 57(2), 163\u2013172. https:\/\/doi.org\/10.1124\/pr.57.2.3","journal-title":"Pharmacological Reviews"},{"key":"11131_CR60","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/980301","volume":"2014","author":"A Nassar","year":"2014","unstructured":"Nassar, A., Elgohary, G., Elhassan, T., et al. (2014). Methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Journal of Transplantation, 2014, Article 980301. https:\/\/doi.org\/10.1155\/2014\/980301","journal-title":"Journal of Transplantation"},{"issue":"12","key":"11131_CR61","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/sj.bmt.1703076","volume":"27","author":"GB Vogelsang","year":"2001","unstructured":"Vogelsang, G. B., & Arai, S. (2001). Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: Preliminary findings. Bone Marrow Transplantation, 27(12), 1255\u20131262. https:\/\/doi.org\/10.1038\/sj.bmt.1703076","journal-title":"Bone Marrow Transplantation"},{"issue":"6","key":"11131_CR62","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/00007691-199512000-00023","volume":"17","author":"JT Ransom","year":"1995","unstructured":"Ransom, J. T. (1995). Mechanism of action of mycophenolate mofetil. Therapeutic Drug Monitoring, 17(6), 681\u2013684. https:\/\/doi.org\/10.1097\/00007691-199512000-00023","journal-title":"Therapeutic Drug Monitoring"},{"issue":"4","key":"11131_CR63","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/00000441-200204000-00005","volume":"323","author":"RW McMurray","year":"2002","unstructured":"McMurray, R. W., & Harisdangkul, V. (2002). Mycophenolate mofetil: Selective T cell inhibition. American Journal of the Medical Sciences, 323(4), 194\u2013196. https:\/\/doi.org\/10.1097\/00000441-200204000-00005","journal-title":"American Journal of the Medical Sciences"},{"issue":"2","key":"11131_CR64","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1046\/j.1523-1755.2001.060002653.x","volume":"60","author":"C Zoja","year":"2001","unstructured":"Zoja, C., Benigni, A., Noris, M., et al. (2001). Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney International, 60(2), 653\u2013663. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.060002653.x","journal-title":"Kidney International"},{"key":"11131_CR65","unstructured":"\u6731\u96ef (2021). \u897f\u7f57\u83ab\u53f8\u8054\u5408\u9499\u8c03\u78f7\u9178\u9176\u6291\u5236\u5242\u6cbb\u7597\u6fc0\u7d20\u8010\u836f\/\u4f9d\u8d56\u7684\u6162\u6027\u79fb\u690d\u7269\u6297\u5bbf\u4e3b\u75c5(cGVHD)[D]. \u4e2d\u56fd\u4eba\u6c11\u89e3\u653e\u519b\u9646\u519b\u519b\u533b\u5927\u5b66, 10.27001\/d.cnki.gtjyu.2021.000145."},{"issue":"3","key":"11131_CR66","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s12185-010-0516-x","volume":"91","author":"C Onishi","year":"2010","unstructured":"Onishi, C., Ohashi, K., Sawada, T., et al. (2010). A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. International Journal of Hematology, 91(3), 464\u2013470. https:\/\/doi.org\/10.1007\/s12185-010-0516-x","journal-title":"International Journal of Hematology"},{"issue":"11","key":"11131_CR67","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/sj.bmt.1703583","volume":"29","author":"L Hambach","year":"2002","unstructured":"Hambach, L., Stadler, M., Dammann, E., et al. (2002). Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplantation, 29(11), 903\u2013906. https:\/\/doi.org\/10.1038\/sj.bmt.1703583","journal-title":"Bone Marrow Transplantation"},{"issue":"2","key":"11131_CR68","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/ejh.13537","volume":"106","author":"N Bejanyan","year":"2021","unstructured":"Bejanyan, N., Rogosheske, J., Cao, Q., et al. (2021). Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation. European Journal of Haematology, 106(2), 205\u2013212. https:\/\/doi.org\/10.1111\/ejh.13537","journal-title":"European Journal of Haematology"},{"issue":"6","key":"11131_CR69","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41409-025-02562-w","volume":"60","author":"L Lopez-Corral","year":"2025","unstructured":"Lopez-Corral, L., Blazquez-Goni, C., Perez-Lopez, E., et al. (2025). GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation. Bone Marrow Transplantation, 60(6), 832\u2013840. https:\/\/doi.org\/10.1038\/s41409-025-02562-w","journal-title":"Bone Marrow Transplantation"},{"issue":"9","key":"11131_CR70","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3760\/cma.j.issn.0253-2727.2020.09.003","volume":"41","author":"W Zhu","year":"2020","unstructured":"Zhu, W., Feng, Y. M., Chen, T., et al. (2020). [The clinical observation of sirolimus combined with calcineurin inhibitors for steroid-resistant\/steroid-dependent extensive cGVHD][J]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 41(9), 716\u2013722. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2020.09.003","journal-title":"Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi"},{"issue":"1","key":"11131_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03243-5","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang, Y., Zou, L., Xu, K., et al. (2024). Long-term safety and influence on growth in patients receiving sirolimus: A pooled analysis. Orphanet Journal of Rare Diseases, 19(1), Article 299. https:\/\/doi.org\/10.1186\/s13023-024-03243-5","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"4","key":"11131_CR72","doi-asserted-by":"publisher","first-page":"124","DOI":"10.31547\/bct-2024-016","volume":"7","author":"R Sharma","year":"2024","unstructured":"Sharma, R., Pardeep, A., De, R., et al. (2024). Sirolimus as add-on therapy to corticosteroids for moderate-severe chronic graft versus host disease[J]. Blood cell therapy, 7(4), 124\u2013128. https:\/\/doi.org\/10.31547\/bct-2024-016","journal-title":"Blood cell therapy"},{"issue":"7","key":"11131_CR73","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","volume":"11","author":"C Cutler","year":"2005","unstructured":"Cutler, C., Henry, N. L., Magee, C., et al. (2005). Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 11(7), 551\u2013557. https:\/\/doi.org\/10.1016\/j.bbmt.2005.04.007","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"2","key":"11131_CR74","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","volume":"19","author":"S Shayani","year":"2013","unstructured":"Shayani, S., Palmer, J., Stiller, T., et al. (2013). Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis. Biology of Blood and Marrow Transplantation, 19(2), 298\u2013304. https:\/\/doi.org\/10.1016\/j.bbmt.2012.10.006","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"1","key":"11131_CR75","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1097\/MPH.0000000000002793","volume":"46","author":"S Paul","year":"2024","unstructured":"Paul, S., Nirmal, G., Chadha, V., et al. (2024). Sirolimus-induced hypertriglyceridemia leads to acute pancreatitis and diabetic ketoacidosis post stem cell transplant for sickle cell disease. Journal of Pediatric Hematology\/Oncology, 46(1), e91\u2013e93. https:\/\/doi.org\/10.1097\/MPH.0000000000002793","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"3","key":"11131_CR76","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41409-017-0025-0","volume":"53","author":"J Uhm","year":"2018","unstructured":"Uhm, J., Shin, E., Michelis, F. V., et al. (2018). Therapeutic efficacy of azathioprine in addition to prednisone-based regimens as first-line chronic graft-versus-host disease treatment. Bone Marrow Transplantation, 53(3), 334\u2013338. https:\/\/doi.org\/10.1038\/s41409-017-0025-0","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"11131_CR77","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/bjc.2014.523","volume":"112","author":"S Chien","year":"2015","unstructured":"Chien, S., Liu, C., Hong, Y., et al. (2015). Use of azathioprine for graft-vs-host disease is the major risk for development of secondary malignancies after haematopoietic stem cell transplantation: A nationwide population-based study. British Journal of Cancer, 112(1), 177\u2013184. https:\/\/doi.org\/10.1038\/bjc.2014.523","journal-title":"British Journal of Cancer"},{"issue":"2","key":"11131_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70473","volume":"9","author":"AM Salehi","year":"2026","unstructured":"Salehi, A. M., Rezaei, R., Sadeghi, A., et al. (2026). Azathioprine increases the risk of non-melanoma skin cancer among organ transplant recipients; an updated systematic review and meta-analysis. Cancer Reports, 9(2), Article e70473. https:\/\/doi.org\/10.1002\/cnr2.70473","journal-title":"Cancer Reports"},{"issue":"1","key":"11131_CR79","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1039\/c1pp05194f","volume":"11","author":"NR Attard","year":"2012","unstructured":"Attard, N. R., & Karran, P. (2012). UVA photosensitization of thiopurines and skin cancer in organ transplant recipients. Photochemical & Photobiological Sciences, 11(1), 62\u201368. https:\/\/doi.org\/10.1039\/c1pp05194f","journal-title":"Photochemical & Photobiological Sciences"},{"issue":"12","key":"11131_CR80","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1182\/blood.V96.12.3995","volume":"96","author":"S Koc","year":"2000","unstructured":"Koc, S., Leisenring, W., Flowers, M. E., et al. (2000). Thalidomide for treatment of patients with chronic graft-versus-host disease[J]. Blood, 96(12), 3995\u20133996.","journal-title":"Blood"},{"issue":"9","key":"11131_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137641","volume":"10","author":"SD Schutt","year":"2015","unstructured":"Schutt, S. D., Fu, J., Nguyen, H., et al. (2015). Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice. PLoS One, 10(9), Article e137641. https:\/\/doi.org\/10.1371\/journal.pone.0137641","journal-title":"PLoS One"},{"issue":"10","key":"11131_CR82","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","volume":"25","author":"EK Waller","year":"2019","unstructured":"Waller, E. K., Miklos, D., Cutler, C., et al. (2019). Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study. Biology of Blood and Marrow Transplantation, 25(10), 2002\u20132007. https:\/\/doi.org\/10.1016\/j.bbmt.2019.06.023","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"21","key":"11131_CR83","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos, D., Cutler, C. S., Arora, M., et al. (2017). Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood, 130(21), 2243\u20132250. https:\/\/doi.org\/10.1182\/blood-2017-07-793786","journal-title":"Blood"},{"issue":"5","key":"11131_CR84","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1182\/bloodadvances.2024014374","volume":"9","author":"J Pidala","year":"2025","unstructured":"Pidala, J., Kim, J., Kalos, D., et al. (2025). Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: A multicenter real-world analysis[J]. Blood Adv, 9(5), 1040\u20131048. https:\/\/doi.org\/10.1182\/bloodadvances.2024014374","journal-title":"Blood Adv"},{"issue":"6","key":"11131_CR85","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oncolo\/oyac042","volume":"27","author":"RQ Le","year":"2022","unstructured":"Le, R. Q., Wang, X., Zhang, H., et al. (2022). FDA approval summary: Ruxolitinib for treatment of chronic graft-versus-host disease after failure of one or two lines of systemic therapy. The Oncologist, 27(6), 493\u2013500. https:\/\/doi.org\/10.1093\/oncolo\/oyac042","journal-title":"The Oncologist"},{"key":"11131_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13071527","author":"B Amoozgar","year":"2025","unstructured":"Amoozgar, B., Bangolo, A., Mohamed, A., et al. (2025). JAK2 inhibitors and emerging therapies in graft-versus-host disease: Current perspectives and future directions. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines13071527","journal-title":"Biomedicines"},{"key":"11131_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.650295","volume":"12","author":"E Huarte","year":"2021","unstructured":"Huarte, E., Peel, M. T., Verbist, K., et al. (2021). Ruxolitinib, a JAK1\/2 inhibitor, ameliorates cytokine storm in experimental models of hyperinflammation syndrome. Frontiers in Pharmacology, 12, Article 650295. https:\/\/doi.org\/10.3389\/fphar.2021.650295","journal-title":"Frontiers in Pharmacology"},{"issue":"23","key":"11131_CR88","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1200\/JCO-24-02477","volume":"43","author":"R Zeiser","year":"2025","unstructured":"Zeiser, R., Russo, D., Ram, R., et al. (2025). Ruxolitinib in patients with corticosteroid-refractory or corticosteroid-dependent chronic graft-versus-host disease: 3-year final analysis of the phase III REACH3 study. Journal of Clinical Oncology\u202f: Official Journal of the American Society of Clinical Oncology, 43(23), 2566\u20132571. https:\/\/doi.org\/10.1200\/JCO-24-02477","journal-title":"Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"11131_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100627","volume":"5","author":"T McManus","year":"2025","unstructured":"McManus, T., Holtzman, N. G., Zhao, A., et al. (2025). Systemic treatment with the Janus kinase inhibitor baricitinib in ocular chronic graft-versus-host disease. Ophthalmology Science, 5(1), Article 100627. https:\/\/doi.org\/10.1016\/j.xops.2024.100627","journal-title":"Ophthalmology Science"},{"issue":"3","key":"11131_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2022.103343","volume":"70","author":"F Ali","year":"2022","unstructured":"Ali, F., & Ilyas, A. (2022). Belumosudil with ROCK-2 inhibition: Chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease. Current Research in Translational Medicine, 70(3), Article 103343. https:\/\/doi.org\/10.1016\/j.retram.2022.103343","journal-title":"Current Research in Translational Medicine"},{"issue":"5","key":"11131_CR91","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1358\/dot.2022.58.5.3400705","volume":"58","author":"B Taylor","year":"2022","unstructured":"Taylor, B., Cohen, J., Tejeda, J., et al. (2022). Belumosudil for chronic graft-versus-host disease. Drugs of Today, 58(5), 203\u2013212. https:\/\/doi.org\/10.1358\/dot.2022.58.5.3400705","journal-title":"Drugs of Today"},{"issue":"22","key":"11131_CR92","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood.2021012021","volume":"138","author":"C Cutler","year":"2021","unstructured":"Cutler, C., Lee, S. J., Arai, S., et al. (2021). Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: The ROCKstar Study. Blood, 138(22), 2278\u20132289. https:\/\/doi.org\/10.1182\/blood.2021012021","journal-title":"Blood"},{"issue":"6","key":"11131_CR93","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41409-025-02554-w","volume":"60","author":"D Michonneau","year":"2025","unstructured":"Michonneau, D., Malard, F., Le Grand, S., et al. (2025). Efficacy and safety of belumosudil for treatment of cGVHD: Multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplantation, 60(6), 779\u2013786. https:\/\/doi.org\/10.1038\/s41409-025-02554-w","journal-title":"Bone Marrow Transplantation"},{"issue":"4","key":"11131_CR94","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41409-024-02507-9","volume":"60","author":"S Heidenreich","year":"2025","unstructured":"Heidenreich, S., Egger-Heidrich, K., Halter, J. P., et al. (2025). Safety and efficacy of the ROCK-2-inhibitor belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis. Bone Marrow Transplantation, 60(4), 439\u2013446. https:\/\/doi.org\/10.1038\/s41409-024-02507-9","journal-title":"Bone Marrow Transplantation"},{"key":"11131_CR95","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1100\/2011\/924954","volume":"11","author":"J Olivieri","year":"2011","unstructured":"Olivieri, J., Coluzzi, S., Attolico, I., et al. (2011). Tirosin kinase inhibitors in chronic graft versus host disease: From bench to bedside. The Scientific World Journal, 11, 1908\u20131931. https:\/\/doi.org\/10.1100\/2011\/924954","journal-title":"The Scientific World Journal"},{"issue":"4","key":"11131_CR96","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41409-022-01898-x","volume":"58","author":"M Srour","year":"2023","unstructured":"Srour, M., Alsuliman, T., Labreuche, J., et al. (2023). Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and\/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): A prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Bone Marrow Transplantation, 58(4), 401\u2013406. https:\/\/doi.org\/10.1038\/s41409-022-01898-x","journal-title":"Bone Marrow Transplantation"},{"key":"11131_CR97","doi-asserted-by":"publisher","first-page":"73795651","DOI":"10.1177\/09636897221113789","volume":"31","author":"DW Baek","year":"2022","unstructured":"Baek, D. W., Cho, H. J., Kim, J. H., et al. (2022). Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD[J]. Cell Transplantation, 31, 73795651. https:\/\/doi.org\/10.1177\/09636897221113789","journal-title":"Cell Transplantation"},{"issue":"5","key":"11131_CR98","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.bbmt.2020.01.014","volume":"26","author":"BE Marinelli","year":"2020","unstructured":"Marinelli, B. E., Costantini, A., Mancini, G., et al. (2020). Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-beta and p-SMAD Pathway[J]. Biology Of Blood And Marrow Transplantation, 26(5), 823\u2013834. https:\/\/doi.org\/10.1016\/j.bbmt.2020.01.014","journal-title":"Biology Of Blood And Marrow Transplantation"},{"issue":"2","key":"11131_CR99","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.bbmt.2017.10.021","volume":"24","author":"GL Chen","year":"2018","unstructured":"Chen, G. L., Carpenter, P. A., Broady, R., et al. (2018). Anti-platelet-derived growth factor receptor alpha chain antibodies predict for response to nilotinib in steroid-refractory or -dependent chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 24(2), 373\u2013380. https:\/\/doi.org\/10.1016\/j.bbmt.2017.10.021","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"3","key":"11131_CR100","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/2040620718756603","volume":"9","author":"C Kuo","year":"2018","unstructured":"Kuo, C., Wang, P., Hwang, W., et al. (2018). Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: Results from the NOVEL study. Therapeutic Advances in Hematology, 9(3), 65\u201378. https:\/\/doi.org\/10.1177\/2040620718756603","journal-title":"Therapeutic Advances in Hematology"},{"key":"11131_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105535","volume":"112","author":"Y Gao","year":"2025","unstructured":"Gao, Y., Liu, R., Shi, J., et al. (2025). Clonal GZMK(+)CD8(+) T cells are identified as a hallmark of the pathogenesis of cGVHD-induced bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. EBioMedicine, 112, Article 105535. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105535","journal-title":"EBioMedicine"},{"issue":"8","key":"11131_CR102","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41418-018-0228-y","volume":"26","author":"Y Jiao","year":"2019","unstructured":"Jiao, Y., Davis, J. E., Rautela, J., et al. (2019). Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes. [J]. Cell Death Differ, 26(8), 1516\u20131530. https:\/\/doi.org\/10.1038\/s41418-018-0228-y","journal-title":"[J]. Cell Death Differ"},{"issue":"11","key":"11131_CR103","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.jid.2020.02.029","volume":"140","author":"J Strobl","year":"2020","unstructured":"Strobl, J., Pandey, R. V., Krausgruber, T., et al. (2020). Anti-apoptotic molecule BCL2 is a therapeutic target in steroid-refractory graft-versus-host disease. [J]. J Invest Dermatol, 140(11), 2188\u20132198. https:\/\/doi.org\/10.1016\/j.jid.2020.02.029","journal-title":"[J]. J Invest Dermatol"},{"issue":"5","key":"11131_CR104","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.3324\/haematol.2018.212837","volume":"104","author":"O Al-Sawaf","year":"2019","unstructured":"Al-Sawaf, O., Herling, C. D., Holtick, U., et al. (2019). Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia. [J]. Haematologica, 104(5), e224\u2013e226. https:\/\/doi.org\/10.3324\/haematol.2018.212837","journal-title":"[J]. Haematologica"},{"key":"11131_CR105","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8831125","volume":"2021","author":"CS Teoh","year":"2021","unstructured":"Teoh, C. S., & Goh, A. S. (2021). Relapsed chronic lymphocytic leukaemia with concomitant extensive chronic graft versus host disease after allogeneic haematopoietic stem cell transplantation successfully treated with oral venetoclax. Case Reports in Transplantation, 2021, Article 8831125. https:\/\/doi.org\/10.1155\/2021\/8831125","journal-title":"Case Reports in Transplantation"},{"issue":"1","key":"11131_CR106","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1182\/blood-2018-03-839993","volume":"133","author":"K Paz","year":"2019","unstructured":"Paz, K., Flynn, R., Du, J., et al. (2019). Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. [J]. Blood, 133(1), 94\u201399. https:\/\/doi.org\/10.1182\/blood-2018-03-839993","journal-title":"[J]. Blood"},{"key":"11131_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109746","volume":"117","author":"X Chen","year":"2023","unstructured":"Chen, X., Wang, Y., Huang, X., et al. (2023). Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice. International Immunopharmacology, 117, Article 109746. https:\/\/doi.org\/10.1016\/j.intimp.2023.109746","journal-title":"International Immunopharmacology"},{"issue":"1","key":"11131_CR108","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3349\/ymj.2015.56.1.112","volume":"56","author":"SH Han","year":"2015","unstructured":"Han, S. H., Kim, J. S., Woo, J. H., et al. (2015). The effect of bortezomib on expression of inflammatory cytokines and survival in a murine sepsis model induced by cecal ligation and puncture. Yonsei Medical Journal, 56(1), 112\u2013123. https:\/\/doi.org\/10.3349\/ymj.2015.56.1.112","journal-title":"Yonsei Medical Journal"},{"issue":"10","key":"11131_CR109","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1182\/blood-2014-02-554279","volume":"124","author":"CC Pai","year":"2014","unstructured":"Pai, C. C., Chen, M., Mirsoian, A., et al. (2014). Treatment of chronic graft-versus-host disease with bortezomib. Blood, 124(10), 1677\u20131688. https:\/\/doi.org\/10.1182\/blood-2014-02-554279","journal-title":"Blood"},{"issue":"3","key":"11131_CR110","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3324\/haematol.2018.188052","volume":"103","author":"PJ Martin","year":"2018","unstructured":"Martin, P. J. (2018). Bortezomib for prevention of acute graft-versus-host disease: A conclusion reached. Haematologica, 103(3), 377\u2013379. https:\/\/doi.org\/10.3324\/haematol.2018.188052","journal-title":"Haematologica"},{"issue":"26","key":"11131_CR111","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1200\/JCO.2012.42.0984","volume":"30","author":"J Koreth","year":"2012","unstructured":"Koreth, J., Stevenson, K. E., Kim, H. T., et al. (2012). Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. Journal of Clinical Oncology, 30(26), 3202\u20133208. https:\/\/doi.org\/10.1200\/JCO.2012.42.0984","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"11131_CR112","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.bbmt.2020.07.005","volume":"26","author":"S Chhabra","year":"2020","unstructured":"Chhabra, S., Visotcky, A., Pasquini, M. C., et al. (2020). Ixazomib for chronic graft-versus-host disease prophylaxis following allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 26(10), 1876\u20131885. https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.005","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"11131_CR113","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016284","author":"T Caballero-Velazquez","year":"2025","unstructured":"Caballero-Velazquez, T., Delgado-Serrano, J., Lopez-Corral, L., et al. (2025). Ixazomib decreases the risk of chronic graft-versus-host disease: Identification of cGvHD biomarkers. Blood Advances. https:\/\/doi.org\/10.1182\/bloodadvances.2025016284","journal-title":"Blood Advances"},{"issue":"2","key":"11131_CR114","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41409-020-01044-5","volume":"56","author":"A Shimoni","year":"2021","unstructured":"Shimoni, A., Shem-Tov, N., Yerushalmi, R., et al. (2021). Carfilzomib combined with cyclosporine and methotrexate for the prevention of graft-versus-host disease after allogeneic stem-cell transplantation from unrelated donors. Bone Marrow Transplantation, 56(2), 451\u2013456. https:\/\/doi.org\/10.1038\/s41409-020-01044-5","journal-title":"Bone Marrow Transplantation"},{"key":"11131_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.578314","volume":"11","author":"N Saidu","year":"2020","unstructured":"Saidu, N., Bonini, C., Dickinson, A., et al. (2020). New approaches for the treatment of chronic graft-versus-host disease: Current status and future directions. Frontiers in Immunology, 11, Article 578314. https:\/\/doi.org\/10.3389\/fimmu.2020.578314","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"11131_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.0022-202X.2003.22133.x","volume":"122","author":"A Leask","year":"2004","unstructured":"Leask, A., Denton, C. P., & Abraham, D. J. (2004). Insights into the molecular mechanism of chronic fibrosis: The role of connective tissue growth factor in scleroderma. Journal of Investigative Dermatology, 122(1), 1\u20136. https:\/\/doi.org\/10.1046\/j.0022-202X.2003.22133.x","journal-title":"Journal of Investigative Dermatology"},{"issue":"10","key":"11131_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203742","volume":"13","author":"S Mukai","year":"2018","unstructured":"Mukai, S., Ogawa, Y., Saya, H., et al. (2018). Therapeutic potential of tranilast for the treatment of chronic graft-versus-host disease in mice. PLoS One, 13(10), Article e203742. https:\/\/doi.org\/10.1371\/journal.pone.0203742","journal-title":"PLoS One"},{"issue":"3","key":"11131_CR118","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/bmt.2009.173","volume":"45","author":"Y Ogawa","year":"2010","unstructured":"Ogawa, Y., Dogru, M., Uchino, M., et al. (2010). Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD. Bone Marrow Transplantation, 45(3), 565\u2013569. https:\/\/doi.org\/10.1038\/bmt.2009.173","journal-title":"Bone Marrow Transplantation"},{"issue":"6","key":"11131_CR119","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.humimm.2019.03.003","volume":"80","author":"W McManigle","year":"2019","unstructured":"McManigle, W., Youssef, A., & Sarantopoulos, S. (2019). B cells in chronic graft-versus-host disease. Human Immunology, 80(6), 393\u2013399. https:\/\/doi.org\/10.1016\/j.humimm.2019.03.003","journal-title":"Human Immunology"},{"key":"11131_CR120","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122430","author":"JC Poe","year":"2018","unstructured":"Poe, J. C., Jia, W., Di Paolo, J. A., et al. (2018). SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.122430","journal-title":"JCI Insight"},{"issue":"3","key":"11131_CR121","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jtct.2022.12.015","volume":"29","author":"C Lin","year":"2023","unstructured":"Lin, C., DiCioccio, R. A., Haykal, T., et al. (2023). A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease[J]. Transplant Cell Ther, 29(3), 171\u2013179. https:\/\/doi.org\/10.1016\/j.jtct.2022.12.015","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"11131_CR122","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1182\/blood-2012-01-403428","volume":"120","author":"P Zerr","year":"2012","unstructured":"Zerr, P., Palumbo-Zerr, K., Distler, A., et al. (2012). Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood, 120(14), 2909\u20132917. https:\/\/doi.org\/10.1182\/blood-2012-01-403428","journal-title":"Blood"},{"issue":"20","key":"11131_CR123","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1158\/1078-0432.CCR-23-0666","volume":"29","author":"E Rodriguez-Arboli","year":"2023","unstructured":"Rodriguez-Arboli, E., Lee, C. J., Caballero-Velazquez, T., et al. (2023). Targeting hedgehog signaling with glasdegib in patients with refractory sclerotic chronic GVHD: A report of two phase I\/II trials. Clinical Cancer Research, 29(20), 4057\u20134067. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0666","journal-title":"Clinical Cancer Research"},{"issue":"45","key":"11131_CR124","doi-asserted-by":"publisher","first-page":"19402","DOI":"10.1073\/pnas.1008247107","volume":"107","author":"D Valmori","year":"2010","unstructured":"Valmori, D., Raffin, C., Raimbaud, I., et al. (2010). Human RORgammat+ TH17 cells preferentially differentiate from naive FOXP3\u2009+\u2009Treg in the presence of lineage-specific polarizing factors[J]. Proc Natl Acad Sci U S A, 107(45), 19402\u201319407. https:\/\/doi.org\/10.1073\/pnas.1008247107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"11131_CR125","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s12276-025-01535-9","volume":"57","author":"E Park","year":"2025","unstructured":"Park, E., & Ciofani, M. (2025). Th17 cell pathogenicity in autoimmune disease. Experimental & Molecular Medicine, 57(9), 1913\u20131927. https:\/\/doi.org\/10.1038\/s12276-025-01535-9","journal-title":"Experimental & Molecular Medicine"},{"key":"11131_CR126","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92111","author":"E Forcade","year":"2017","unstructured":"Forcade, E., Paz, K., Flynn, R., et al. (2017). An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.92111","journal-title":"JCI Insight"},{"issue":"6","key":"11131_CR127","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jpha.2023.05.009","volume":"13","author":"J Zeng","year":"2023","unstructured":"Zeng, J., Li, M., Zhao, Q., et al. (2023). Small molecule inhibitors of RORgammat for Th17 regulation in inflammatory and autoimmune diseases[J]. J Pharm Anal, 13(6), 545\u2013562. https:\/\/doi.org\/10.1016\/j.jpha.2023.05.009","journal-title":"J Pharm Anal"},{"issue":"2","key":"11131_CR128","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41375-024-02475-5","volume":"39","author":"F Lyu","year":"2025","unstructured":"Lyu, F., Gong, H., Wu, X., et al. (2025). Dimethyl fumarate ameliorates chronic graft-versus-host disease by inhibiting Tfh differentiation via Nrf2. Leukemia, 39(2), 473\u2013481. https:\/\/doi.org\/10.1038\/s41375-024-02475-5","journal-title":"Leukemia"},{"key":"11131_CR129","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00833","volume":"10","author":"W Li","year":"2019","unstructured":"Li, W., Qu, G., Choi, S. C., et al. (2019). Targeting T cell activation and lupus autoimmune phenotypes by inhibiting glucose transporters. Frontiers in Immunology, 10, Article 833. https:\/\/doi.org\/10.3389\/fimmu.2019.00833","journal-title":"Frontiers in Immunology"},{"key":"11131_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11110736","author":"K Mhandire","year":"2021","unstructured":"Mhandire, K., Saggu, K., & Buxbaum, N. P. (2021). Immunometabolic therapeutic targets of graft-versus-host disease (GvHD). Metabolites. https:\/\/doi.org\/10.3390\/metabo11110736","journal-title":"Metabolites"},{"issue":"2","key":"11131_CR131","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/1744666X.2023.2279188","volume":"20","author":"A Salhotra","year":"2024","unstructured":"Salhotra, A., Falk, L., Park, G., et al. (2024). A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease. Expert Review of Clinical Immunology, 20(2), 169\u2013184. https:\/\/doi.org\/10.1080\/1744666X.2023.2279188","journal-title":"Expert Review of Clinical Immunology"},{"issue":"22","key":"11131_CR132","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth, J., Matsuoka, K., Kim, H. T., et al. (2011). Interleukin-2 and regulatory T cells in graft-versus-host disease. The New England Journal of Medicine, 365(22), 2055\u20132066. https:\/\/doi.org\/10.1056\/NEJMoa1108188","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"11131_CR133","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","volume":"128","author":"J Koreth","year":"2016","unstructured":"Koreth, J., Kim, H. T., Jones, K. T., et al. (2016). Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood, 128(1), 130\u2013137. https:\/\/doi.org\/10.1182\/blood-2016-02-702852","journal-title":"Blood"},{"issue":"16","key":"11131_CR134","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1182\/bloodadvances.2023009729","volume":"7","author":"H Wobma","year":"2023","unstructured":"Wobma, H., Kapadia, M., Kim, H. T., et al. (2023). Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Advances, 7(16), 4647\u20134657. https:\/\/doi.org\/10.1182\/bloodadvances.2023009729","journal-title":"Blood Advances"},{"key":"11131_CR135","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231152644","volume":"14","author":"A Ngwube","year":"2023","unstructured":"Ngwube, A., Rangarajan, H., & Shah, N. (2023). Role of abatacept in the prevention of graft-versus-host disease: Current perspectives. Therapeutic Advances in Hematology, 14, Article 1564070404. https:\/\/doi.org\/10.1177\/20406207231152644","journal-title":"Therapeutic Advances in Hematology"},{"issue":"25","key":"11131_CR136","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2017-05-780239","volume":"131","author":"MR Nahas","year":"2018","unstructured":"Nahas, M. R., Soiffer, R. J., Kim, H. T., et al. (2018). Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood, 131(25), 2836\u20132845. https:\/\/doi.org\/10.1182\/blood-2017-05-780239","journal-title":"Blood"},{"issue":"24","key":"11131_CR137","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1182\/blood.2022019107","volume":"141","author":"AG Koshy","year":"2023","unstructured":"Koshy, A. G., Kim, H. T., Liegel, J., et al. (2023). <article-title update=\"added\">Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease. Blood, 141(24), 2932\u20132943. https:\/\/doi.org\/10.1182\/blood.2022019107","journal-title":"Blood"},{"issue":"3","key":"11131_CR138","doi-asserted-by":"publisher","DOI":"10.1177\/00185787241310874","volume":"60","author":"TL Levien","year":"2025","unstructured":"Levien, T. L., & Baker, D. E. (2025). Axatilimab. Hospital Pharmacy, , Article 159012198. https:\/\/doi.org\/10.1177\/00185787241310874","journal-title":"Hospital Pharmacy"},{"key":"11131_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104855","volume":"215","author":"EI Bahbah","year":"2025","unstructured":"Bahbah, E. I., Attia, M., & Ali, M. (2025). Efficacy and safety of axatilimab in chronic graft-versus-host disease: A systematic review and meta-analysis. Critical Reviews in Oncology\/Hematology, 215, Article 104855. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104855","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"6","key":"11131_CR140","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/1750743X.2025.2501928","volume":"17","author":"T Dexter","year":"2025","unstructured":"Dexter, T., Anthias, C., & Nicholson, E. (2025). Evaluating axatilimab as a treatment option for chronic graft-versus-host disease. Immunotherapy, 17(6), 409\u2013418. https:\/\/doi.org\/10.1080\/1750743X.2025.2501928","journal-title":"Immunotherapy"},{"issue":"11","key":"11131_CR141","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","volume":"391","author":"D Wolff","year":"2024","unstructured":"Wolff, D., Cutler, C., Lee, S. J., et al. (2024). Axatilimab in recurrent or refractory chronic graft-versus-host disease. The New England Journal of Medicine, 391(11), 1002\u20131014. https:\/\/doi.org\/10.1056\/NEJMoa2401537","journal-title":"The New England Journal of Medicine"},{"issue":"17","key":"11131_CR142","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1158\/1078-0432.CCR-25-0896","volume":"31","author":"RQ Le","year":"2025","unstructured":"Le, R. Q., Godder, K., Wang, J., et al. (2025). FDA approval summary: Axatilimab for adult and pediatric patients weighing at least 40 kilograms with chronic GVHD after two prior lines of systemic therapy. Clinical Cancer Research, 31(17), 3607\u20133612. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0896","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"11131_CR143","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","volume":"108","author":"C Cutler","year":"2006","unstructured":"Cutler, C., Miklos, D., Kim, H. T., et al. (2006). Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 108(2), 756\u2013762. https:\/\/doi.org\/10.1182\/blood-2006-01-0233","journal-title":"Blood"},{"issue":"20","key":"11131_CR144","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2017-05-786137","volume":"130","author":"F Malard","year":"2017","unstructured":"Malard, F., Labopin, M., Yakoub-Agha, I., et al. (2017). Rituximab-based first-line treatment of cGVHD after allogeneic SCT: Results of a phase 2 study. Blood, 130(20), 2186\u20132195. https:\/\/doi.org\/10.1182\/blood-2017-05-786137","journal-title":"Blood"},{"key":"11131_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2023.101959","volume":"81","author":"PR Colunga-Pedraza","year":"2023","unstructured":"Colunga-Pedraza, P. R., Barbosa-Castillo, L. M., Coronado-Alejandro, E. U., et al. (2023). Low-dose rituximab in steroid-refractory chronic graft-versus-host disease. Transplant Immunology, 81, Article 101959. https:\/\/doi.org\/10.1016\/j.trim.2023.101959","journal-title":"Transplant Immunology"},{"issue":"6","key":"11131_CR146","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/TP.0b013e318183f662","volume":"86","author":"M von Bonin","year":"2008","unstructured":"von Bonin, M., Oelschl\u00e4gel, U., Radke, J., et al. (2008). Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation, 86(6), 875\u2013879. https:\/\/doi.org\/10.1097\/TP.0b013e318183f662","journal-title":"Transplantation"},{"issue":"9","key":"11131_CR147","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bbmt.2009.04.003","volume":"15","author":"MA Kharfan-Dabaja","year":"2009","unstructured":"Kharfan-Dabaja, M. A., Mhaskar, A. R., Djulbegovic, B., et al. (2009). Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: A systematic review and meta-analysis. Biology of Blood and Marrow Transplantation\u202f: Journal of the American Society for Blood and Marrow Transplantation, 15(9), 1005\u20131013. https:\/\/doi.org\/10.1016\/j.bbmt.2009.04.003","journal-title":"Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation"},{"issue":"12","key":"11131_CR148","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","volume":"14","author":"J Casan","year":"2018","unstructured":"Casan, J., Wong, J., Northcott, M. J., et al. (2018). Anti-CD20 monoclonal antibodies: Reviewing a revolution. Human Vaccines & Immunotherapeutics, 14(12), 2820\u20132841. https:\/\/doi.org\/10.1080\/21645515.2018.1508624","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"12","key":"11131_CR149","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s43018-020-00133-0","volume":"1","author":"I Solomon","year":"2020","unstructured":"Solomon, I., Amann, M., Goubier, A., et al. (2020). CD25-T(reg)-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nature Cancer, 1(12), 1153\u20131166. https:\/\/doi.org\/10.1038\/s43018-020-00133-0","journal-title":"Nature Cancer"},{"issue":"2","key":"11131_CR150","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjh.19958","volume":"206","author":"A Zhang","year":"2025","unstructured":"Zhang, A., Huang, Z., Zhang, R., et al. (2025). Humanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 206(2), 615\u2013627. https:\/\/doi.org\/10.1111\/bjh.19958","journal-title":"British Journal of Haematology"},{"issue":"3","key":"11131_CR151","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1046\/j.1365-2141.2001.02582.x","volume":"112","author":"W Willenbacher","year":"2001","unstructured":"Willenbacher, W., Basara, N., Blau, I. W., et al. (2001). Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. British Journal of Haematology, 112(3), 820\u2013823. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02582.x","journal-title":"British Journal of Haematology"},{"key":"11131_CR152","doi-asserted-by":"publisher","unstructured":"Zhu, X. L., Wang, J. Z., Fu, H. X. Efficacy and safety of basiliximab in gastrointestinal chronic graft-versus-host disease[J]. Zhonghua xue ye xue za zhi\u2009=\u2009Zhonghua xueyexue zazhi, 2026,47(2):146\u2013152. https:\/\/doi.org\/10.3760\/cma.j.cn121090-20250630-00306","DOI":"10.3760\/cma.j.cn121090-20250630-00306"},{"issue":"8","key":"11131_CR153","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.4049\/jimmunol.1402785","volume":"194","author":"K Ohnuma","year":"2015","unstructured":"Ohnuma, K., Hatano, R., Aune, T. M., et al. (2015). Regulation of pulmonary graft-versus-host disease by IL-26\u2009+\u2009CD26+CD4 T lymphocytes. Journal of Immunology (Baltimore, Md.\u202f: 1950), 194(8), 3697\u20133712. https:\/\/doi.org\/10.4049\/jimmunol.1402785","journal-title":"Journal of Immunology (Baltimore, Md. : 1950)"},{"issue":"12","key":"11131_CR154","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1111\/ajt.17178","volume":"22","author":"R Hatano","year":"2022","unstructured":"Hatano, R., Itoh, T., Otsuka, H., et al. (2022). Humanized anti-IL-26 monoclonal antibody as a novel targeted therapy for chronic graft-versus-host disease. American Journal of Transplantation, 22(12), 2804\u20132820. https:\/\/doi.org\/10.1111\/ajt.17178","journal-title":"American Journal of Transplantation"},{"key":"11131_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.785774","volume":"12","author":"Y Gao","year":"2021","unstructured":"Gao, Y., Shan, W., Gu, T., et al. (2021). Daratumumab prevents experimental xenogeneic graft-versus-host disease by skewing proportions of T cell functional subsets and inhibiting T cell activation and migration. Frontiers in Immunology, 12, Article 785774. https:\/\/doi.org\/10.3389\/fimmu.2021.785774","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"11131_CR156","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.clml.2020.01.010","volume":"20","author":"L Nikolaenko","year":"2020","unstructured":"Nikolaenko, L., Chhabra, S., Biran, N., et al. (2020). Graft-versus-host disease in multiple myeloma patients treated with daratumumab after allogeneic transplantation. Clinical Lymphoma, Myeloma & Leukemia, 20(6), 407\u2013414. https:\/\/doi.org\/10.1016\/j.clml.2020.01.010","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"3","key":"11131_CR157","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1759720X17690474","volume":"9","author":"CS Guerreiro","year":"2017","unstructured":"Guerreiro, C. S., & Isenberg, D. A. (2017). Belimumab in systemic lupus erythematosus (SLE): Evidence-to-date and clinical usefulness. Therapeutic Advances in Musculoskeletal Disease, 9(3), 75\u201385. https:\/\/doi.org\/10.1177\/1759720X17690474","journal-title":"Therapeutic Advances in Musculoskeletal Disease"},{"issue":"18","key":"11131_CR158","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1182\/blood.2020008040","volume":"137","author":"W Jia","year":"2021","unstructured":"Jia, W., Poe, J. C., Su, H., et al. (2021). BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation. Blood, 137(18), 2544\u20132557. https:\/\/doi.org\/10.1182\/blood.2020008040","journal-title":"Blood"},{"key":"11131_CR159","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.995149","volume":"13","author":"Y Jeon","year":"2022","unstructured":"Jeon, Y., Lim, J. Y., Im, K. I., et al. (2022). BAFF blockade attenuates acute graft-versus-host disease directly via the dual regulation of T- and B-cell homeostasis. Frontiers in Immunology, 13, Article 995149. https:\/\/doi.org\/10.3389\/fimmu.2022.995149","journal-title":"Frontiers in Immunology"},{"key":"11131_CR160","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143605","author":"N Maximova","year":"2023","unstructured":"Maximova, N., Nistico, D., Riccio, G., et al. (2023). Advantage of first-line therapeutic drug monitoring-driven use of infliximab for treating acute intestinal and liver GVHD in children: A prospective, single-center study. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15143605","journal-title":"Cancers (Basel)"},{"issue":"2","key":"11131_CR161","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1620\/tjem.251.81","volume":"251","author":"K Kamachi","year":"2020","unstructured":"Kamachi, K., Ando, T., Tsuruoka, N., et al. (2020). Successful anti-TNF-alpha therapy for Crohn\u2019s disease after allogeneic stem cell transplantation: A case report. The Tohoku Journal of Experimental Medicine, 251(2), 81\u201385. https:\/\/doi.org\/10.1620\/tjem.251.81","journal-title":"The Tohoku Journal of Experimental Medicine"},{"issue":"3","key":"11131_CR162","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.medcli.2011.03.006","volume":"137","author":"C Motllo","year":"2011","unstructured":"Motllo, C., Ferra, C., Lopez, L., et al. (2011). [Salvage treatment with infliximab of steroid-resistant graft-versus-host disease in allogeneic transplanted patients][J]. Med Clin (Barc), 137(3), 115\u2013118. https:\/\/doi.org\/10.1016\/j.medcli.2011.03.006","journal-title":"Med Clin (Barc)"},{"issue":"7","key":"11131_CR163","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.bbmt.2008.04.006","volume":"14","author":"M Hamadani","year":"2008","unstructured":"Hamadani, M., Hofmeister, C. C., Jansak, B., et al. (2008). Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biology of Blood and Marrow Transplantation\u202f: Journal of the American Society for Blood and Marrow Transplantation, 14(7), 783\u2013789. https:\/\/doi.org\/10.1016\/j.bbmt.2008.04.006","journal-title":"Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation"},{"key":"11131_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061396","author":"S Rolla","year":"2020","unstructured":"Rolla, S., Maglione, A., De Mercanti, S. F., et al. (2020). The meaning of immune reconstitution after alemtuzumab therapy in multiple sclerosis. Cells. https:\/\/doi.org\/10.3390\/cells9061396","journal-title":"Cells"},{"issue":"5","key":"11131_CR165","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.bbmt.2013.02.009","volume":"19","author":"S Nikiforow","year":"2013","unstructured":"Nikiforow, S., Kim, H. T., Bindra, B., et al. (2013). Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 19(5), 804\u2013811. https:\/\/doi.org\/10.1016\/j.bbmt.2013.02.009","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"5","key":"11131_CR166","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3324\/haematol.2011.054577","volume":"97","author":"CH Gutierrez-Aguirre","year":"2012","unstructured":"Gutierrez-Aguirre, C. H., Cantu-Rodriguez, O. G., Borjas-Almaguer, O. D., et al. (2012). Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. Haematologica, 97(5), 717\u2013722. https:\/\/doi.org\/10.3324\/haematol.2011.054577","journal-title":"Haematologica"},{"key":"11131_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178620","author":"Y Niu","year":"2025","unstructured":"Niu, Y., Liu, C., Li, P., et al. (2025). Interleukin networks in GVHD: Mechanistic crosstalk, therapeutic targeting, and emerging paradigms. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms26178620","journal-title":"International Journal of Molecular Sciences"},{"issue":"12","key":"11131_CR168","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/j.bbmt.2011.07.001","volume":"17","author":"WR Drobyski","year":"2011","unstructured":"Drobyski, W. R., Pasquini, M., Kovatovic, K., et al. (2011). Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biology of Blood and Marrow Transplantation, 17(12), 1862\u20131868. https:\/\/doi.org\/10.1016\/j.bbmt.2011.07.001","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"4","key":"11131_CR169","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3724\/zdxbyxb-2022-0245","volume":"51","author":"J Chen","year":"2022","unstructured":"Chen, J., Lu, J., Hong, X., et al. (2022). Tocilizumab combined with ruxolitinib in the treatment of children with steroid resistant graft versus host disease after hematopoietic stem cell transplantation: Report of 6 cases. Zhejiang Da Xue Xue Bao Yi Xue Ban, 51(4), 470\u2013473. https:\/\/doi.org\/10.3724\/zdxbyxb-2022-0245","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"issue":"5","key":"11131_CR170","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1097\/TP.0000000000003489","volume":"105","author":"MH Parker","year":"2021","unstructured":"Parker, M. H., Stone, D., Abrams, K., et al. (2021). Anti-ICOS mAb targets pathogenic IL-17A-expressing cells in canine model of chronic GVHD. Transplantation, 105(5), 1008\u20131016. https:\/\/doi.org\/10.1097\/TP.0000000000003489","journal-title":"Transplantation"},{"issue":"1","key":"11131_CR171","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03307-8","volume":"26","author":"T Hasegawa","year":"2024","unstructured":"Hasegawa, T., Utsunomiya, A., Chino, T., et al. (2024). Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model. Arthritis Research & Therapy, 26(1), Article 94. https:\/\/doi.org\/10.1186\/s13075-024-03307-8","journal-title":"Arthritis Research & Therapy"},{"issue":"3","key":"11131_CR172","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213170","volume":"14","author":"AG Laing","year":"2019","unstructured":"Laing, A. G., Fanelli, G., Ramirez-Valdez, A., et al. (2019). Mesenchymal stem cells inhibit T-cell function through conserved induction of cellular stress. PLoS One, 14(3), Article e213170. https:\/\/doi.org\/10.1371\/journal.pone.0213170","journal-title":"PLoS One"},{"issue":"2","key":"11131_CR173","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2023.5757","volume":"10","author":"R Huang","year":"2024","unstructured":"Huang, R., Chen, T., Wang, S., et al. (2024). Mesenchymal stem cells for prophylaxis of chronic graft-vs-host disease after haploidentical hematopoietic stem cell transplant: An open-label randomized clinical trial. JAMA Oncology, 10(2), 220\u2013226. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5757","journal-title":"JAMA Oncology"},{"key":"11131_CR174","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126731","author":"N Kim","year":"2024","unstructured":"Kim, N., Min, G. J., Im, K. I., et al. (2024). Repeated infusions of bone-marrow-derived mesenchymal stem cells over 8 weeks for steroid-refractory chronic graft-versus-host disease: A prospective, phase I\/II clinical study. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms25126731","journal-title":"International Journal of Molecular Sciences"},{"key":"11131_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.697854","volume":"12","author":"WW Guo","year":"2021","unstructured":"Guo, W. W., Su, X. H., Wang, M. Y., et al. (2021). Regulatory T cells in GVHD therapy. Frontiers in Immunology, 12, Article 697854. https:\/\/doi.org\/10.3389\/fimmu.2021.697854","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"11131_CR176","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","volume":"133","author":"P Trzonkowski","year":"2009","unstructured":"Trzonkowski, P., Bieniaszewska, M., Juscinska, J., et al. (2009). First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4\u2009+\u2009CD25+CD127- T regulatory cells. Clinical Immunology, 133(1), 22\u201326. https:\/\/doi.org\/10.1016\/j.clim.2009.06.001","journal-title":"Clinical Immunology"},{"issue":"21","key":"11131_CR177","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.1182\/bloodadvances.2021006625","volume":"6","author":"JS Whangbo","year":"2022","unstructured":"Whangbo, J. S., Nikiforow, S., Kim, H. T., et al. (2022). A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Advances, 6(21), 5786\u20135796. https:\/\/doi.org\/10.1182\/bloodadvances.2021006625","journal-title":"Blood Advances"},{"issue":"6","key":"11131_CR178","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.stem.2024.05.004","volume":"31","author":"H Yano","year":"2024","unstructured":"Yano, H., Koga, K., Sato, T., et al. (2024). Human iPSC-derived CD4(+) Treg-like cells engineered with chimeric antigen receptors control GvHD in a xenograft model. Cell Stem Cell, 31(6), 795\u2013802. https:\/\/doi.org\/10.1016\/j.stem.2024.05.004","journal-title":"Cell Stem Cell"},{"issue":"16","key":"11131_CR179","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu, Y., Zhang, M., Yang, T., et al. (2024). Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis. The New England Journal of Medicine, 390(16), 1467\u20131480. https:\/\/doi.org\/10.1056\/NEJMoa2313812","journal-title":"The New England Journal of Medicine"},{"key":"11131_CR180","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1646421","volume":"16","author":"L Heger","year":"2025","unstructured":"Heger, L., Berking, C., & Hackstein, H. (2025). Extracorporeal photopheresis reduces the T cell stimulatory capacity of human primary blood conventional dendritic cells type 1. Frontiers in Immunology, 16, Article 1646421. https:\/\/doi.org\/10.3389\/fimmu.2025.1646421","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"11131_CR181","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.21873\/invivo.14115","volume":"39","author":"N Gawlik-Rzemieniewska","year":"2025","unstructured":"Gawlik-Rzemieniewska, N., Klima, A., Panek, K., et al. (2025). Regulatory T-cell activation pathways in patients with chronic graft-versus-host disease undergoing extracorporeal photopheresis treatment: A single-center pilot study. In Vivo, 39(6), 3143\u20133160. https:\/\/doi.org\/10.21873\/invivo.14115","journal-title":"In Vivo"},{"key":"11131_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107387","volume":"134","author":"SM Linn","year":"2023","unstructured":"Linn, S. M., Novitzky-Basso, I., Patriquin, C., et al. (2023). Single centre retrospective analysis of extracorporeal photopheresis (ECP) therapy in patients heavily pre-treated for chronic graft-versus-host disease (cGvHD) with steroid failure. Leukemia Research, 134, Article 107387. https:\/\/doi.org\/10.1016\/j.leukres.2023.107387","journal-title":"Leukemia Research"},{"issue":"4","key":"11131_CR183","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41409-020-01122-8","volume":"56","author":"K Maas-Bauer","year":"2021","unstructured":"Maas-Bauer, K., Kiote-Schmidt, C., Bertz, H., et al. (2021). Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease. Bone Marrow Transplantation, 56(4), 909\u2013916. https:\/\/doi.org\/10.1038\/s41409-020-01122-8","journal-title":"Bone Marrow Transplantation"},{"issue":"2","key":"11131_CR184","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jtct.2024.11.004","volume":"31","author":"Z DeFilipp","year":"2025","unstructured":"DeFilipp, Z., Fox, L., Holderried, T. A. W., et al. (2025). Systematic review and meta-analysis of extracorporeal photopheresis for the treatment of steroid-refractory chronic graft-versus-host disease. Transplantation and cellular therapy, 31(2), 71\u201376. https:\/\/doi.org\/10.1016\/j.jtct.2024.11.004","journal-title":"Transplantation and cellular therapy"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11131-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:24:59Z","timestamp":1781648699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-026-11131-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":184,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["11131"],"URL":"https:\/\/doi.org\/10.1007\/s12015-026-11131-7","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}